SCHEMBL273541

SCHEMBL273541

O=C(Nc1ccc(Br)cc1C(=O)N/N=C/c1ccc(Cl)c(C(F)(F)F)c1)c1cccc(CSc2ccncc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 8/20 0.46
SLC34A1 Q06495 1/20 0.46
SLC34A3 Q8N130 1/20 0.46
SLC20A1 Q8WUM9 1/20 0.46
POLB P06746 4/20 0.45
LMNA P02545 3/20 0.45
NPC1 O15118 2/20 0.41
PKM P14618 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 2/20 0.39
MAPT P10636 3/20 0.38
KMT2A Q03164 3/20 0.38
HPGD P15428 2/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PSMD14 O00487 1/20 0.38
THRB P10828 1/20 0.38
ADCYAP1R1 P41586 2/20 0.38
HTT P42858 2/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267708 1.00 SLC34A2 (0.46) SLC34A2SLC34A1SLC34A3SLC20A1POLB
SCHEMBL266306 0.92 MAPT (0.42) SLC34A2SLC34A1SLC34A3SLC20A1POLB
SCHEMBL273401 0.92 MAPT (0.42) SLC34A2SLC34A1SLC34A3SLC20A1POLB
SCHEMBL266977 0.87 POLB (0.51) SLC34A2SLC34A1SLC34A3SLC20A1POLB
SCHEMBL273681 0.87 POLB (0.51) SLC34A2SLC34A1SLC34A3SLC20A1POLB
SCHEMBL273976 0.86 SLC34A2 (0.44) SLC34A2SLC34A1SLC34A3SLC20A1POLB
SCHEMBL266177 0.86 SLC34A2 (0.44) SLC34A2SLC34A1SLC34A3SLC20A1POLB
SCHEMBL265319 0.86 SLC34A2 (0.57) SLC34A2SLC34A1SLC34A3SLC20A1POLB
SCHEMBL274060 0.86 SLC34A2 (0.57) SLC34A2SLC34A1SLC34A3SLC20A1POLB
SCHEMBL273927 0.86 NPC1 (0.48) POLBLMNANPC1PKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885SLC34A1 1/4885SLC34A3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.